Polar Capital Holdings Plc Purchases 418,673 Shares of Enliven Therapeutics, Inc. $ELVN

Polar Capital Holdings Plc increased its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 13.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,513,680 shares of the company’s stock after acquiring an additional 418,673 shares during the quarter. Polar Capital Holdings Plc owned approximately 0.06% of Enliven Therapeutics worth $54,111,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Enliven Therapeutics during the 4th quarter valued at about $83,000. Quantbot Technologies LP grew its position in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $95,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $42.55 on Wednesday. The business’s 50 day simple moving average is $41.61 and its 200 day simple moving average is $31.08. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $48.53. The firm has a market cap of $2.59 billion, a PE ratio of -25.48 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director owned 51,884 shares of the company’s stock, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on ELVN. Stifel Nicolaus began coverage on shares of Enliven Therapeutics in a report on Tuesday, June 9th. They set a “buy” rating and a $60.00 target price on the stock. HC Wainwright upped their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. The Goldman Sachs Group increased their price objective on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $63.40.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.